Drug Discrimination in Methadone-Maintained Humans Study 1

Summary

This study involves giving psychoactive drugs intramuscularly (injected into the muscle of the upper arm or the hip) and/or orally, and measuring the subject's ability to tell the difference between one drug and another, as well as measuring the effects of the drugs on mood, physiology (e.g., heart rate, blood pressure, respiration rate) and behavior. Each subject will receive 2-4 of the listed interventions.

Conditions

• Drug Dependence

Interventions

DRUG

Cycloserine

Cycloserine: 500, 675, 750 mg oral capsule may possibly be given

DRUG

Diltiazem

Diltiazem: 30, 60, 120 mg oral capsule may possibly be

DRUG

Gabapentin

Gabapentin: 100, 200, 400 mg oral capsule may possibly be given

DRUG

Isradipine

Isradipine: 5, 10 mg oral capsule may possibly be given

DRUG

Naloxone

Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given

DRUG

Nifedipine

Nifedipine: 5, 10, 20 mg oral capsule may possibly be given

DRUG

Placebo

Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given

DEVICE

Saline

Saline: I.M. injection may possibly be given

DRUG

Verapamil

Verapamil: 30, 60, 120 mg oral capsule may possibly be given

Sponsors & Collaborators

• University of Arkansas

  lead OTHER

Principal Investigators

• Alison Oliveto, PhD · University of Arkansas

Study Design

Allocation

NA

Masking

DOUBLE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2006-09-30

Primary Completion

2010-05-31

Completion

2010-05-31

Countries

• United States

Study Locations